Biolab Sanus Farmaceutica Ltda

Biolab Sanus Farmaceutical Ltda.

Artur Franz Keppler

Sérgio Luiz Sacurai

Carlos Eduardo Da Costa Touzarim

Gilberto De Nucci

Marcio Henrique Zaim

Márcio Henrique Zaim

Sergio Luiz Sacurai

Carlos Eduardo Touzarim

This invention describes new antifungal compounds that are aralkyl benzyl ethers of the formula (I): where Ar represents aryl, imidazolil, 1,2,4-triazolyl, benzimidazolil;R, R, Rand Rare independently hydrogen, halogen, Calkyl;Rrepresents halogen, Calkyl or O&#x2014;R' where R&#x2032; represents hydrogen or lower alkyl;Rrepresents aryl, substituted aryl, trifluoromethyl, trichloromethyl or O&#x2014;R&#x2032; where R&#x2032; represents hydrogen or lower alkyl; being the substituents of the aryl a halogen or a radical tetrazolyl;n and m represent independently an integer between 0 and 5;With the proviso that when Ar is imidazolil, Ris chlorine, Ris p-phenyl and R, R, Rand Rare hydrogen, n must be different from 2. When n and m are not 0 and 1, Ror Rcan be represented by substituents not necessarily equal.

Benzyl aralkyl ether compounds, method for preparing same, intermediate compounds, use of said compounds, method for treatment and/or prevention, pharmaceutical composition and medicament containing same

A series of derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione, mixtures thereof, their pharmaceutically acceptable salts, which are inhibitors of PDE-5, possessing vasodilatator properties and relaxing effects. In particular, compounds of formula (I), where R, R, R, and Rare defined herein, processes for the preparation of said compounds, pharmaceutical compositions containing them, as well as uses as inhibitors of the enzyme phosphodiesterase type 5 (PDE-5) in the treatment of the erectile dysfunction and PDE-5 inhibitor treatable disorders. 

Derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,9-dione as PDE-5 inhibitors

Growing community of inventors

Santo André-SP, Brazil

Artur Franz Keppler